Molecular Biology Reports

, Volume 42, Issue 3, pp 713–720 | Cite as

Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma

  • Zehra Oksuz
  • Mehmet Sami Serin
  • Engin Kaplan
  • Aylin Dogen
  • Seda Tezcan
  • Gonul Aslan
  • Gurol Emekdas
  • Orhan Sezgin
  • Engin Altintas
  • Eyup Naci Tiftik
Article

Abstract

Recently, serum miRNAs have been evolved as possible biomarkers for different diseases including hepatocellular carcinoma and other types of cancers. Investigating certain serum miRNAs as novel non-invasive markers for early detection of HCV-positive cirrhosis and hepatocellular carcinoma (HCC). The expression profiles of 58 miRNA were analyzed in patient’s plasma of chronic hepatitis C (CHC), HCV-positive cirrhosis and HCV-positive HCC and compared with control group samples. Totally 94 plasma samples; 64 patient plasma (26 CHC, 30 HCV-positive cirrhosis, 8 HCV-positive HCC) and 28 control group plasma, were included. The expression profiles of 58 miRNAs were detected for all patient and control group plasma samples by qRT-PCR using BioMarkTM 96.96 Dynamic Array (Fluidigm Corporation) system. In CHC group, expression profiles of miR-30a-5p, miR-30c-5p, miR-206 and miR-302c-3p were found significantly deregulated (p < 0.05) when compared versus control group. In HCV-positive cirrhosis group, expression profiles of miR-30c-5p, miR-223-3p, miR-302c-3p, miR-17-5p, miR-130a-3p, miR-93-5p, miR-302c-5p and miR-223-3p were found significantly deregulated (p < 0.05). In HCV-positive HCC group, expression profiles of miR-17-5p, miR-223-3p and miR-24-3p were found significant (p < 0.05). When all groups were compared versus control, miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p were found significantly deregulated for cirrhosis and HCC. These results imply that miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers of HCV-positive HCC in very early, even at cirrhosis stage of liver disease.

Keywords

Cirrhosis Hepatocellular carcinoma miRNA HCV Tumor biomarker 

Notes

Acknowledgments

All authors thank to Mersin University Scientific Research Fund for their financial support [Project no. BAP-SBE FM (ZÖ) 2011-5 YL].

References

  1. 1.
    Murakami Y, Tanaka M, Toyoda H, Hayashi K, Kuroda M, Tajima A, Shimotohno K (2010) Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C. BMC Med Genomics 3:48CrossRefPubMedCentralPubMedGoogle Scholar
  2. 2.
    Ferlay J, Bray F, Pisani P, Parkin DM (2004) GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide, version 2.0, IARC CancerBase No. 5. IARC Press, LyonGoogle Scholar
  3. 3.
    Sun J, Haiqi LuH, Wang X, Jin H (2013) MicroRNAs in Hepatocellular Carcinoma: regulation, Function, and clinical implications. ScientificWorldJournal 2013:924206. doi: 10.1155/2013/924206 PubMedCentralPubMedGoogle Scholar
  4. 4.
    Kremsdorf D, Soussan P, Paterlini-Brechot P, Brechot C (2006) Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene 25(27):3823–3833CrossRefPubMedGoogle Scholar
  5. 5.
    Zhang Y, Wei W, Cheng N, Wang K, Li B, Jiang X, Sun S (2012) Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 56:1631–1640CrossRefPubMedGoogle Scholar
  6. 6.
    Dash S, Haque S, Joshi V, Prabhu R, Hazari S, Fermin C, Garry R (2005) HCV-hepatocellular carcinoma: new findings and hope for effective treatment. Microsc Res Tech 68:130–148CrossRefPubMedGoogle Scholar
  7. 7.
    Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, Wang JF, Zhang Z, Lu S, Huang X, Wang Z, Qiu S, Wang X, Yang G, Sun H, Tang Z, Wu Y, Zhu H, Fan J (2011) Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 29:4781–4788CrossRefPubMedGoogle Scholar
  8. 8.
    Qi P, Cheng SQ, Wang H, Li N, Chen YF, Gao CF (2011) Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One 6(12):e28486CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Sunakozaka H, Sakai Y, Horimoto K, Kaneko S (2009) Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 49:1098–1112CrossRefPubMedGoogle Scholar
  10. 10.
    Etheridge A, Lee I, Hood L, Galas D, Wang K (2011) Extracellular microRNA: a new source of biomarkers. Mutat Res 717:85–90CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Shwetha S, Gouthamchandra K, Chandra M, Ravishankar B, Khaja MN, Das S (2013) Circulating miRNA profile in HCV infected serum: novel insight into pathogenesis. Sci Rep 3:1555CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    Ishida H, Tatsumi T, Hosui A, Nawa T, Kodama T, Shimizu S, Hikita H, Hiramatsu N, Kanto T, Hayashi N, Takehara T (2011) Alterations in microRNA expression profile in HCV-infected hepatoma cells: involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway. Biochem Biophys Res Commun 412:92–97CrossRefPubMedGoogle Scholar
  13. 13.
    Diaz G, Melis M, Tice A, Kleiner DE, Mishra L, Zamboni F, Farci P (2013) Identification of microRNAs specifically expressed in hepatitis C virus-associated hepatocellular carcinoma. Int J Cancer 133(4):819–824. doi: 10.1002/ijc.28075 CrossRefGoogle Scholar
  14. 14.
    Gorur A, Balci Fidanci S, Dogruer Unal N, Ayaz L, Akbayir S, Yildirim Yaroglu H, Dirlik M, Serin MS, Tamer L (2012) Determination of plasma microRNA for early detection of gastric cancer. Mol Biol Rep 40(3):2091–2096. doi: 10.1007/s11033-012-2267-7 CrossRefPubMedGoogle Scholar
  15. 15.
    Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, Wells M, Guerrero M, Asara JM, Libermann TA, Afdhal NH (2008) Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res 14:470–477CrossRefPubMedGoogle Scholar
  16. 16.
    Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, David M (2007) Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449:919–922CrossRefPubMedCentralPubMedGoogle Scholar
  17. 17.
    Chen Xian-Ming (2009) MicroRNA signatures in liver diseases. World J Gastroenterol 15:1665–1672CrossRefPubMedCentralPubMedGoogle Scholar
  18. 18.
    Nohata N, Hanazawa T, Enokida H, Seki N (2012) microRNA-1/133a and microRNA-206/133b clusters: dysregulation and functional roles in human cancers. Oncotarget 3:9–21PubMedCentralPubMedGoogle Scholar
  19. 19.
    Lakner AM, Bonkovsky HL, Schrum LW (2011) microRNAs: fad or future of liver disease. World J Gastroenterol 17:2536–2542CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Zhao WY, Wang DD, Song MQ, Yang L, Ye J, Chen LB (2011) Role of microRNA-223 and its target gene oncogene c-myc in hepatocellular carcinoma pathogenesis. Zhonghua Gan Zang Bing Za Zhi 19:114–117PubMedGoogle Scholar
  21. 21.
    Xu H, He JH, Xiao ZD, Zhang QQ, Chen YQ, Zhou H, Qu LH (2010) Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology 52:1431–1442CrossRefPubMedGoogle Scholar
  22. 22.
    Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A (2008) miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol 48:648–656CrossRefPubMedGoogle Scholar
  23. 23.
    Hou W, Tian Q, Zheng J, Bonkovsky HL (2010) MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology 51:1494–1504CrossRefPubMedCentralPubMedGoogle Scholar
  24. 24.
    Liu X, Wang T, Wakita T, Yang W (2010) Systematic identification of microRNA and messenger RNA profiles in hepatitis C virus-infected human hepatoma cells. Virology 398:57–67CrossRefPubMedGoogle Scholar
  25. 25.
    Scagnolari C, Zingariello P, Vecchiet J, Selvaggi C, Racciatti D, Taliani G, Riva E, Pizzigallo E, Antonelli G (2010) Differential expression of interferon-induced microRNAs in patients with chronic hepatitis C virus infection treated with pegylated interferon alpha. Virol J 7:311CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, Schmidt S, Janssen J, Koppe C, Knolle P, Castoldi M, Tacke F, Trautwein C, Luedde T (2011) Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 53:209–218CrossRefPubMedGoogle Scholar
  27. 27.
    Kwiecinski MEN, Noetel A, Schievenbusch S, Strack I, Toex U, Drebber U, Steffen H, Dienes HP, Odenthal M (2010) miR-29, inhibiting synthesis of profibrogenic mediators, is released into the blood stream after chronic hepatitis C infection, indicating progression of fibrosis. Hepatology 52(4 Suppl):119AGoogle Scholar
  28. 28.
    Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D (2013) Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog 52:297–303CrossRefPubMedGoogle Scholar
  29. 29.
    Wong QW, Ching AK, Chan AW, Choy KW, To KF, Lai PB, Wong N (2010) MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res 16:867–875CrossRefPubMedGoogle Scholar
  30. 30.
    Han ZB, Zhong L, Teng MJ, Fan JW, Tang HM, Wu JY, Chen HY, Wang ZW, Qiu GQ, Peng ZH (2012) Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation. Mol Oncol 6:445–457CrossRefPubMedGoogle Scholar
  31. 31.
    Chen L, Jiang M, Yuan W, Tang H (2012) miR-17-5p as a novel prognostic marker for hepatocellular carcinoma. J Invest Surg 25:156–161CrossRefPubMedGoogle Scholar
  32. 32.
    Wang G, Kwan BC, Lai FM, Chow KM, Li PK, Szeto CC (2012) Urinary miR-21, miR-29, and miR-93: novel biomarkers of fibrosis. Am J Nephrol 36:412–418CrossRefPubMedGoogle Scholar
  33. 33.
    Schwabe RF (2011) Wang TC (2011) Targeting liver cancer: first steps toward a miracle? Cancer Cell 20:698–699CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  • Zehra Oksuz
    • 1
  • Mehmet Sami Serin
    • 1
    • 2
  • Engin Kaplan
    • 2
  • Aylin Dogen
    • 1
  • Seda Tezcan
    • 3
  • Gonul Aslan
    • 3
  • Gurol Emekdas
    • 3
  • Orhan Sezgin
    • 4
  • Engin Altintas
    • 4
  • Eyup Naci Tiftik
    • 5
  1. 1.Department of Pharmaceutical Microbiology, Faculty of PharmacyMersin UniversityMersinTurkey
  2. 2.Advanced Technology, Research, and Education CentreMersin UniversityMersinTurkey
  3. 3.Department of Medical Microbiology, Faculty of MedicineMersin UniversityMersinTurkey
  4. 4.Department of Gastroenterology, Faculty of MedicineMersin UniversityMersinTurkey
  5. 5.Department of Hematology, Faculty of MedicineMersin UniversityMersinTurkey

Personalised recommendations